Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NANO.PA
- Price
- 2.95
- Stock movement up
- +0.07 (2.25%)
- Company name
- Nanobiotix S.A
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 139.84M
- Ent value
- 181.97M
- Price/Sales
- 3.07
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -7.00%
- 1 year return
- -43.21%
- 3 year return
- -18.95%
- 5 year return
- -14.82%
- 10 year return
- -17.07%
Last updated: 2025-04-12
DIVIDENDS
NANO.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.07 |
| Price to Book | - |
| EV to Sales | 4.00 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 47.40M |
| EPS (TTM) | -1.31 |
| FCF per share (TTM) | -0.74 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 45.50M |
| Gross profit (TTM) | 47.61M |
| Operating income (TTM) | -53.73M |
| Net income (TTM) | -61.57M |
| EPS (TTM) | -1.31 |
| EPS (1y forward) | -0.91 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 104.65% |
| Operating margin (TTM) | -118.10% |
| Profit margin (TTM) | -135.33% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 66.33M |
| Net receivables | 3.12M |
| Total current assets | 80.46M |
| Goodwill | 0.00 |
| Intangible assets | 9.00K |
| Property, plant and equipment | 0.00 |
| Total assets | 86.68M |
| Accounts payable | 4.77M |
| Short/Current long term debt | 49.17M |
| Total current liabilities | 56.52M |
| Total liabilities | 108.46M |
| Shareholder's equity | -21.78M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -27.25M |
| Capital expenditures (TTM) | 979.50K |
| Free cash flow (TTM) | -34.91M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -71.03% |
| Return on Invested Capital | 367.00% |
| Cash Return on Invested Capital | 208.11% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.91 |
| Daily high | 2.98 |
| Daily low | 2.83 |
| Daily Volume | 159K |
| All-time high | 24.44 |
| 1y analyst estimate | 11.70 |
| Beta | 1.40 |
| EPS (TTM) | -1.31 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 20 May 2025 |
Downside potential
Loading...
Downside potential data
| NANO.PA | S&P500 | |
| Current price drop from All-time high | -87.93% | -12.89% |
| Highest price drop | -93.21% | -56.47% |
| Date of highest drop | 4 May 2023 | 9 Mar 2009 |
| Avg drop from high | -49.41% | -11.07% |
| Avg time to new high | 398 days | 12 days |
| Max time to new high | 2698 days | 1805 days |
COMPANY DETAILS
Marketcap
139.84M
Marketcap category
Small-cap
Description
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
Employees
110
Website
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, April 14, 2...
April 14, 2025
Despite a significant net loss, Nanobiotix SA (NBTX) extends its cash runway and strengthens its partnership with Johnson & Johnson.
April 4, 2025
Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lu...
April 2, 2025
Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CESTPARIS and CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBT...
March 31, 2025
Data show favorable safety and confirm injection feasibility in 12 patients with locally advanced NSCLC amenable to re-irradiation for whom prior lines of therapy have failedA preliminary review of su...
March 27, 2025
Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients with u...
March 20, 2025
Conference call and webcast scheduled for March 18, 2025, at 8:30 A.M. EDT / 1:30 P.M. CETPARIS and CAMBRIDGE, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – th...
March 17, 2025
We recently published a list of 7 Best Nanotech Penny Stocks to Invest In. In this article, we are going to take a look at where Nanobiotix (NASDAQ:NBTX) stands against other best nanotech penny stock...
February 14, 2025
PARIS and CAMBRIDGE, Mass., Jan. 29, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based a...
January 29, 2025
NBTX stock rises following initiation of dosing in a mid-stage NSCLC study evaluating a potential first-in-class radioenhancer, JNJ-1900.
January 21, 2025
Next page